Literature DB >> 9039734

Histiocyte disorders.

D K Webb1.   

Abstract

Histiocyte disorders are characterised by tissue infiltration with cells of monocyte/macrophage lineage, with two disorders, Langerhans' cell histiocytosis (LCH) and haemophagocytic lymphohistiocytosis (HLH) accounting for the overwhelming majority of cases in childhood and, apart from monocyte variants of acute myeloid leukaemia, histiocytic malignancy is very rare. Although both LCH and HLH are considered reactive disorders, the prognosis of these conditions differs greatly, LCH is usually self limiting, with a mortality of 10%, but HLH is usually fatal, with a mortality of over 80% in the absence of bone marrow transplantation. Increased levels of cytokines have been demonstrated in these disorders, and may be responsible for many of the clinical features: it is unclear whether histiocytes themselves, or other immune cells, particularly T lymphocytes, are the abnormal cell population. Due to the rarity of histiocyte disorders, collaborative studies are essential to improve understanding and advance treatment.

Entities:  

Mesh:

Year:  1996        PMID: 9039734     DOI: 10.1093/oxfordjournals.bmb.a011585

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  3 in total

Review 1.  Fatal juvenile xanthogranuloma presenting as a sellar lesion: case report and literature review.

Authors:  Sherise D Ferguson; Steven G Waguespack; Lauren A Langford; Joann L Ater; Ian E McCutcheon
Journal:  Childs Nerv Syst       Date:  2014-12-12       Impact factor: 1.475

2.  Multisystem Langerhans cell histiocytosis presenting as an oral lesion.

Authors:  Kallarakkal Thomas George; Ramanathan Anand; Sockalingam Ganasalingam; Rosnah B Zain
Journal:  J Oral Maxillofac Pathol       Date:  2013-01

Review 3.  Hemophagocytic Lymphohistiocytosis in Langerhans Cell Histiocytosis: A Case Report and Review of the Literature.

Authors:  Ashley R P Hinson; Niraj Patel; Joel Kaplan
Journal:  J Pediatr Hematol Oncol       Date:  2021-01       Impact factor: 1.170

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.